Anúncio
Anúncio

PHAT

PHAT logo

Phathom Pharmaceuticals, Inc. Common Stock

15.02
USD
Patrocinado
-0.58
-3.74%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

15.49

+0.48
+3.19%

Relatórios de Lucros PHAT

Rácio de surpresa positiva

PHAT separação 14 de 25 últimas estimativas.

56%

Próximo Relatório

Data do Próximo Relatório
04 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$57.08M
/
-$0.39
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+15.31%
/
-4.88%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+92.43%
/
-62.86%

Phathom Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 30 de out. de 2025, PHAT reported earnings of -0.41 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 26.25% surprise. Revenue reached 49.50 milhão, compared to an expected 47.93 milhão, with a 3.28% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analistas forecast an EPS of -0.39 USD, with revenue projected to reach 57.08 milhão USD, implying an diminuir of -4.88% EPS, and aumentar of 15.31% in Revenue from the last quarter.
FAQ
For Q3 2025, Phathom Pharmaceuticals, Inc. Common Stock reported EPS of -$0.41, beating estimates by 26.25%, and revenue of $49.50M, 3.28% above expectations.
The stock price moved down -1.63%, changed from $13.53 before the earnings release to $13.31 the day after.
The next earning report is scheduled for 04 de mar. de 2026.
Based on 11 analistas, Phathom Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $57.08M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio